U.S. COVID-19 booster debate moves to FDA vaccine advisory committee

Published by

By Manojna Maddipatla (Reuters) – The debate over whether Americans should receive a booster dose of the Pfizer/BioNTech COVID-19 vaccine moves to a panel of independent expert advisers to the U.S. Food and Drug Administration on Friday. While U.S. health officials, some other countries and vaccine makers have said boosters are needed, many scientists and vaccine experts disagree. The FDA staff said in documents https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-third-covid-19-shot-warranted-fda-document-2021-09-15 prepared for the committee this week that the vaccine Pfiz…

Read More